P2, N=20, Recruiting, University of Washington | N=40 --> 20 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

Notably, in the triplet combination of IO with P-gp and PARP inhibitors, PARP inhibition of the repair of DNA damage caused by calicheamicin accumulation following P-gp inhibition markedly enhanced the antitumor effects of IO. This approach may offer a novel and effective therapeutic strategy for IO-resistant B-ALL.

P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

P3, N=750, Not yet recruiting, Charite University, Berlin, Germany

P1/2, N=23, Not yet recruiting, University of Utah

ADCT-601 demonstrates robust AXL expression linked to anti-tumor activity in preclinical models of ACC, establishing a proof-of-concept for targeting AXL in this rare cancer. These findings support clinical translation of AXL-targeting ADC as a novel biomarker-driven therapy for patients in ACC.

P2, N=133, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P3, N=700, Recruiting, University of Birmingham | Active, not recruiting --> Recruiting

P2, N=49, Recruiting, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Recruiting

P2, N=50, Recruiting, Istituto Clinico Humanitas | Active, not recruiting --> Recruiting

P3, N=130, Recruiting, PedAL BCU, LLC | N=98 --> 130

The patient achieved complete remission following the standard 7 + 3 induction chemotherapy regimen for AML with gemtuzumab ozogamicin. This case illustrates the diagnostic challenges posed by concomitant class-defining alterations in hematologic neoplasms and underscores the importance of integrated genomic assessment.